Skip to content

Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects

Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00931060
Enrollment
24
Registered
2009-07-02
Start date
2007-11-30
Completion date
2009-06-30
Last updated
2009-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases, Hepatic Encephalopathy, Hepatic Insufficiency

Keywords

Ammonia, Citric acid cycle, Branched Chain Amino Acids

Brief summary

The purpose of this study is to determine whether Branched chain Amino Acids enhances the uptake of ammonia in muscle tissue.

Detailed description

Branched-chain amino acids (BCAA; leucine, valine, isoleucine) are used to prevent hepatic encephalopathy in cirrhotic patients. The main effect of BCAAs is believed to take place in muscles where BCAAs provide carbon-skeletons for the TCA-cycle. This enhances the conversion of alfa-ketoglutarate to ammonia via glutamine. We intend to study the effect of oral administered BCAA on the metabolism of ammonia and amino acids across the leg-muscles by means of catheters inserted into the femoral artery (A) and vein (V). Muscle blood flow (F; L/min) will be determined by constant infusion of indocyanine green and indicator dilution principle. Arterial blood flow and A and V concentrations of ammonia and amino acids will be measured before an oral load of BCAA (0.45 g BCAA/kg body weight) and after 1 and 3 hours. The metabolism of ammonia will also be estimated by means of 13N-NH3 PET scans. Hypothesis: BCAA increases the uptake of ammonia in muscle tissue and lowers arterial ammonia.

Interventions

DIETARY_SUPPLEMENTBranched chain amino acids

Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 patients with liver cirrhosis * 6 healthy subjects age and sex matched

Exclusion criteria

* Non-treated diabetes * Pregnancy/breast-feeding

Design outcomes

Primary

MeasureTime frame
arterial ammonia concentration1 and 3 hours

Secondary

MeasureTime frame
muscle ammonia metabolism1 hour and 3 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026